Neurotrope (NASDAQ:NTRP) Trading Up 5.7%
Neurotrope Inc (NASDAQ:NTRP)’s share price was up 5.7% during mid-day trading on Wednesday . The stock traded as high as $6.00 and last traded at $5.96, approximately 123,623 shares were traded during trading. An increase of 44% from the average daily volume of 86,073 shares. The stock had previously closed at $5.64.
Several equities research analysts have recently issued reports on NTRP shares. ValuEngine raised Neurotrope from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research raised Neurotrope from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Wednesday. Finally, Janney Montgomery Scott started coverage on Neurotrope in a research report on Tuesday, June 18th. They set a “buy” rating and a $14.00 target price for the company.
The firm has a fifty day moving average of $5.86 and a two-hundred day moving average of $5.90. The company has a market cap of $73.05 million, a PE ratio of -4.09 and a beta of 2.43.
About Neurotrope (NASDAQ:NTRP)
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Recommended Story: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.